Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results

Gilead Sciences (GILD) Potential M&A In Focus

Despite Gilead Sciences (NASDAQ: GILD) reporting solid fourth quarter earnings, an aggressive $12 billion buyback, and raised dividend after the close, much of the talk on the Street today centered around the company's M&A strategy.

Piper Jaffray analyst Joshua Schimmer said... More

Gilead (GILD) Needs Impactful M&A for the Next Leg of Growth - Piper Jaffray

Piper Jaffray analyst, Joshua Schimmer, is hoping to see an impactful acquisition to propel Gilead Sciences (NASDAQ: GILD) into its next leg of growth. However, at 7x next year's eps, the stock may have hit bottom.

GILD reported a very strong 4Q15, bolstered by strong HCV sales in Japan, partially offset by limited VA HCV starts in the quarter. The company guided to flat/slightly down product sales in 2016 and a significant uptick in R&D (+12%-23%) and SG&A (+2%-12%). The company is increasing its dividend... More

Standpoint Research Starts Gilead Sciences (GILD) at Buy

Standpoint Research initiated coverage on Gilead Sciences (NASDAQ: GILD) with a Buy rating and a price target of $110.00.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $82.71 yesterday.

Japanese Hep C Boosts Gilead Sciences (GILD) in the Qtr - Baird

Baird analyst Brian Skorney reiterated an Outperform rating and $135 price target on Gilead Sciences (NASDAQ: GILD) following Q4 results which beat on Japanese Hep C.

Skorney commented, "Gilead delivered another top- and bottom-line beat, driven by Japanese Hep C sales. We... More

Gilead's (GILD) Increased Unit Sales Tempered By Lower Prices - Oppenheimer

Oppenheimer analyst, Wendy Lam, trimmed her price target on Gilead Sciences (NASDAQ: GILD) as the increasing volume of Harvoni will be offset by reductions in price. One bright note was the strong start to HIV as Genvoya generated $44B in sales. PT is cut to $120 from $124 but maintaining the Outperform rating.

GILD reported 4Q15 revenue of $8.5B and non-GAAP EPS of $3.32, topping Street consensus estimates of $8.2B and $3.00. However, GILD's 2016 guidance on net product sales of... More

Gilead Sciences (GILD) Declares $0.43 Quarterly Dividend; Adds $12B to Stock Buyback Plan

Gilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.43 per share, or $1.72 annualized.

The dividend will be payable on March 30, 2016, to stockholders of record on March 16, 2016, with an ex-dividend date of March 14, 2016.

The annual yield on the dividend is 2.1 percent.

In addition the Board authorized an increase of 4 cents (ten percent) in the companys quarterly dividend program,... More

Gilead Sciences (GILD) Tops Q4 EPS by 32c

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $3.32, $0.32 better than the analyst estimate of $3.00. Revenue for the quarter came in at $8.51 billion versus the consensus estimate of $8.13 billion.

Product Sales

Total product sales for the fourth quarter of 2015 were $8.4 billion compared to $7.2 billion for the fourth quarter of 2014. In the fourth quarter of 2015, product sales in the U.S. were $4.8 billion compared to $5.5 billion in the fourth quarter of 2014. In Europe, product sales were $1.7 billion compared to $1.4 billion in the fourth quarter of 2014. Sales in other international locations increased to $1.9... More